Overview

Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty

Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
0
Participant gender:
All
Summary
The number of patients requiring joint replacement is increasing due to its success in restoring function and pain relief, and the growing population of the elderly. One of the most serious complications of arthroplasty is joint prosthesis infection. Due to the absence of prospective, randomized, controlled studies, there is no consensus concerning diagnosis and treatment of prosthetic joint infections. The main objective of this trial is to evaluate the clinical efficacy of rifampin combination therapy versus monotherapy using cloxacillin or vancomycin in early staphylococcal infections after total hip and knee arthroplasty.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Oslo University Hospital
Treatments:
Anti-Bacterial Agents
Anti-Infective Agents
Cloxacillin
Rifampin
Vancomycin
Criteria
Inclusion Criteria:

- Prosthetic joint infections category 2 or 3 (early post.op infections within 4 weeks).

- Diagnosis of staphylococci.

- Clinically and radiographically stable implants kept in place after revision.

Exclusion Criteria:

- Infection with other microorganisms than staphylococci.

- Less than 2 years of expected survival.

- Predictable inability to comply with the treatment and/or follow-up visits.

- Contraindication to the use of study medication including acute or chronic liver
disease.

- Lack of written consent.

- Fertile women.

- Patients taking less than 80% of the study medication.